Bio-Rad Laboratories Inc (BIO)vsStryker Corporation (SYK)
BIO
Bio-Rad Laboratories Inc
$264.49
-0.19%
HEALTHCARE · Cap: $7.14B
SYK
Stryker Corporation
$335.67
-1.20%
HEALTHCARE · Cap: $128.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 872% more annual revenue ($25.12B vs $2.58B). BIO leads profitability with a 29.4% profit margin vs 12.9%. BIO appears more attractively valued with a PEG of 1.19. SYK earns a higher WallStSmart Score of 65/100 (C+).
BIO
Buy60
out of 100
Grade: C
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.1%
Fair Value
$189.38
Current Price
$264.49
$75.11 premium
Margin of Safety
+14.5%
Fair Value
$392.65
Current Price
$335.67
$56.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
3.9% revenue growth
Weak financial health signals
Earnings declined 83.0%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BIO
The strongest argument for BIO centers on P/E Ratio, Price/Book, Altman Z-Score. Profitability is solid with margins at 29.4% and operating margin at 8.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : BIO
The primary concerns for BIO are Revenue Growth, Piotroski F-Score, EPS Growth.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 40.0x leaves little room for execution misses.
Key Dynamics to Monitor
BIO carries more volatility with a beta of 1.20 — expect wider price swings.
SYK is growing revenue faster at 11.4% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (65/100 vs 60/100) and 11.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?